Methods for forming implantable compositions are provided. In some embodiments, the methods include (i) providing a gel base, (ii) adding water and a hydrating agent to the gel base to form a mixture, (iii) reducing the water content of the mixture; and (iv) adding a delivered material before, during, and/or after step (ii) or (iii). The water content is reduced to about 5% or less by weight of the implantable composition.

Methods, compositions and kits for producing functional chondrocytes, skeletal cells, bone marrow stromal cells, and progenitor cells thereof are provided. These methods, compositions and kits find use in producing chondrocytes, osteoblasts, stromal cells, and progenitor cells thereof in vivo, or in vitro for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the cartilage, bone and hematopoietic system. In some embodiments, specific combinations of protein factors are identified for reprogramming non-skeletal cells into bones, hematopoietic stroma, and chondrocytes, which may be provided in vitro or in vivo.

The application is related to a method for preparing an induced osteogenesis formulation, the method comprises the following steps: (1) a human dental matrix is decalcified; (2) then an exogenous active protein BMP, i.e. bone morphogenetic protein is added to the decalcified dental matrix, resulting in the induced osteogenesis formulation

The invention is a method of applying a joint inducing protein preferably BMP-9 or BMP-3 to an ossification center in order to create a joint, articular cartilage, or an endochondral cap. The ossification center may be one that occurs naturally such as in the case of amputation, wound healing or fracture, or, it may be artificially induced by the application of an ossification center inducing protein, which may include other BMP family proteins such as BMP-2, BMP-4 or BMP-7. Further, this invention is a method of producing joints, or joint-like structures in vitro by application of BMP-9 to cells derived from tissue regions capable of producing ossification centers, such as digit-derived fibroblasts.

The present disclosure is directed to hybrid multifunctional macromers that can self-assemble to form nanoparticles for on-demand and targeted release of morphogens. Embodiments of the disclosure can include the hybrid multifunctional macromers and peptide sequences incorporated therein, self-assembled nanoparticles including the hybrid multifunctional macromers, methods for producing the hybrid multifunctional macromers and peptide sequences, and methods for treating a disease by the on-demand and targeted delivery of a compound using the hybrid multifunctional macromers.

Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.

A new composition has been developed that incorporates S1P into a conventional demineralized bone matrix material. Once the device is implanted into the spine, the S1P will elute out of the device, thereby setting up a concentration gradient in the vicinity of the device. This gradient will cause stem cells to preferentially migrate to the device.

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.

Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.

Non-thermal Atmospheric Plasma (NAP) from a plasma source is mixed with a liquid medium and the resulting compound is applied to the scalp to treat hair loss. The NAP-medium compound may be applied to the surface of the scalp, or produced in situ, or injected into the scalp.